79.52 USD
↗ 0.19 (0.24%)AT CLOSE (03:59 PM EDT)
Dianthus Therapeutics, Inc. Common Stock
DNTHNASDAQ • USD
79.53
↗ 0.01 (0.01%)
POST MARKET (AS OF 07:30 PM EDT)
Post Market
AS OF 07:30 PM EDT
79.53
↗ 0.01 (0.01%)
Market: CLOSED
Dianthus Therapeutics, Inc. Common Stock (DNTH) trades at $79.45 per share. Technicals currently rate "Neutral" while our fundamental analysis reads "Neutral". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 2/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.
Technical & fundamental data as of Oct 27, 2026.
Open?$79.55
High?$81.10
Low?$78.64
Prev. Close?$79.33
Volume?748.7K
Avg. Volume?1.0M
VWAP?$79.77
Rel. Volume?0.74x
Bid / Ask
Bid?$31.89 × 100
Ask?$99.94 × 100
Spread?$68.05
Midpoint?$65.91
Valuation & Ratios
Market Cap?4.4B
Shares Out?54.8M
Float?48.8M
Float %?89.0%
P/E Ratio?N/A
P/B Ratio?3.80
EPS?-$3.44
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
Employees
92
Market Cap
4.4B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2023-09-12
Address
7 TIMES SQUARE
NEW YORK, NY 10036
Phone: 929-999-4055
NEW YORK, NY 10036
Phone: 929-999-4055
Technical OutlookNeutral
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?12
Z-Score?100
Momentum?48
Short Sent.?39
Piotroski F-Score?2/9Weak
Altman Z-Score?64.32Safe
Confidence?55%Low
Short InterestVery High
Short % of Float?18.42%High
Short Interest?9.0M
Days to Cover?10.2
Free Float48.8M
Avg Daily Volume883.4K
Settlement Date2026-10-15
Financial Health
Current Ratio?26.10Strong
Quick Ratio?26.10Strong
Cash Ratio?3.21Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score58/100
P/E?N/A▾
P/B?3.80FAIR▾
Peers100
S&P46
P/S?2,336.08HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-19.9CHEAP▾
S&P97
EV/Sales?2,278.02HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-16.4%WEAK▾
S&P8
ROA?-15.9%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-155709000
Enterprise Value?$4.3B
Fundamentals ratios updated end of day